Human papillomavirus (HPV) has been identified as the leading cause of cervical cancer in women as well as a growing risk factor in
oropharyngeal cancer. Although over 150 related HPV strains have been identified, only a subset have been identified as major risk factors
for cervical cancer. While HPV16 and HPV18 have clearly been implicated as causative agents, the influence of other high-risk HPV genotypes
on the severity and progression of cervical cancer (e.g., viral load; persistence and clearance rates of virus over time) have been reported. In
particular, the co-infection of high-risk HPV strains has now been identified as risk factors for increased co-morbidity and disease progression.
Outcome-based clinical studies in association with HPV vaccines studies demonstrate the advantages of long-term monitoring for multiple
viral genotype infections in association with continued efficacy and cross-genotype protectiveness. Unfortunately, the diagnostic tools to
detect, identify and quantitatively assess the co-infection of multiple HPV genotypes have not been available.
Anyplex™ II HPV HR Detection is specifically designed for simultaneous detection and quantification of 14 high-risk HPV genotypes including
HPV16 and HPV18 which contributes to cervical cancer. Anyplex™ II HPV HR Detection is a fast, reliable and quantitative solution for the
detection of HPV infection, providing a much-needed multiplex diagnostic solution to assist in prognosis and long-term patient outcome.